Onartuzumab
Based on 2 publication(s) in Google Scholar
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.62%
- CAS No.: 1133766-06-9
- Molecular Weight:98.907 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Onartuzumab
More-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
Biological Activity
Description
Isotype
(Fab-G1-kappa)-(Fc-G1)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
HGFR/c-Met
In Vitro
Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET[1].
Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3]
-
Dosage:30 mg/kg
-
Administration:IP, twice a week for 2 mouth
-
Result:Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.
-
Animal Model:U-87 MG tumor-bearing mice[3]
-
Dosage:30 mg/kg
-
Administration:IP, once
-
Result:Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
(Fab-G1-kappa)-(Fc-G1)
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Onartuzumab can bind Human c-MET/HGFR Protein (ECD, His Tag). The EC50 for this effect is 4.21 ng/mL. -
Flow cytometric analysis of 1.5×106 MDA-MB-231 cells with Onartuzumab (HY-P99250, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1133766-06-9
-
Appearance Liquid
-
Molecular Weight 98.907 kDa
-
Color Colorless to light yellow
-
SMILES
[Onartuzumab]
-
Synonyms
MetMAb
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. [Abstract]2026 Mar 20:e16557. PMID: 41861091
Onartuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar 20:e16557. [Abstract]
A CCK-8 proliferation assay was used to assess the proliferation of HCT116 and DLD-1 cells; these cells were seeded in the lower chambers of Transwell inserts and co-cultured with LX-2 cells placed in the upper chambers. The MET-blocking antibody Onartuzumab (10 µg/mL) was added to evaluate the role of the MET signaling pathway.
Onartuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar 20:e16557. [Abstract]
Transwell migration assays were used to evaluate the chemotactic migration of HCT116 and DLD-1 cells toward LX-2 cells seeded in the lower chamber. Onartuzumab (10 µg/mL) was used to block the MET signaling pathway. Representative images are shown.
-
Mol Pharm
Synthesis and Evaluation of a Novel c-Met-Targeting Cyclic Peptide as a Potential Diagnostic Agent for Colorectal Cancer. [Abstract]2024 Jul 1;21(7):3613-3622. PMID: 38853512
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. [Content Brief]
[2]. Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)